Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Wednesday, September 15: 5:30 – 8:00 AM ET / 5:30 PM – 8:00 PM China Time

17:30-17:40, Company introduction / history / vision (Speaker: Glen McLaughlin)
17:40-18:05, Quantitative Imaging – Sound Speed Map（Speaker: David Napolitano）
18:05-18:30, CEUS and its quantification（Speaker: Zhaoling Lu）
18:30-19:00, Clinical application of photoacoustic/ultrasonic (PA/US) imaging in human superficial lesions (Speaker: Meng Yang）
19:00-19:25, Carotid blood flow a standardized protocol to assess and interpret the quantitative analysis with HiFR-vector flow (Speaker: Alfredo Goddi)
19:25-19:50, Future of image formation methods along with a vision for an open architecture platform for clinical and translational use（Speaker: Glen McLaughlin）
19:50-20:00, Close out with Mindray’s commitment to excellence.（Speaker: Glen McLaughlin）

Verasonics, Inc.
Monday, September 13: 12:15 – 1:15 PM ET
An Overview of the HIFUPlex Elite USgFUS Platforms for Small and Large Subjects
Speaker: Peter Kaczkowski
Tuesday, September 14: 1:30 – 2:30 PM ET
Ultrafast Volume Imaging and the Vantage system
Speakers: Miguel Bernal and Bryan Cunitz
Wednesday, September 15: 1:30 – 2:30 PM ET
SoniVue NDE Research Software
Speakers: Jack Potter and Daniel Rohrbach

VINNO Technology (Suzhou) Co., Ltd
Sunday, September 12: 4:00 – 5:00 PM
Echocardiography in heart function assessment disclose the effect of legumain as a potential therapeutic target in acute myocardial infarction
Speaker: Hui Yang
Combination of XianGui capsule and LCZ696 inhibits doxorubicin-induced heart failure in mice
Heart failure occurs in the final stages of various heart diseases. Its morbidity and mortality are high, resulting in frequent hospitalizations that will greatly reduce the quality of life of patients. Buchang XianGui capsule is one of traditional Chinese medicines for the treatment of hypotension, which can effectively improve heart function. LCZ696 (Sacubatril and Valsartan Sodium Tablets) is a new type of angiotensin receptor neprilysin inhibitor, which can significantly improve the symptoms of heart failure patient, but also cause side effects. In our study, we used doxorubicin (DOX)-induced heart failure mouse model to investigate the therapeutic effect and involved mechanism of XG combined with LCZ696 on heart failure. C57BL/6 mice were divided into control group, DOX group, XG group, LCZ696 group and combination group. After the administration, mice heart functions, blood pressure, and serum cardiac injury markers were detected. Heart sections were conducted with HE, Sirius Red and immunohistochemical staining. We found that XG combined with LCZ696 can improve DOX-induced heart failure, which is related to alleviating myocardial fibrosis, cardiomyocyte oxidative injury, apoptosis, and inflammation. Our research is expected to provide a reference for the application of XG and new strategy for clinical treatment of heart failure.
Speaker: Yajun Duan

Monday, September 13: 4:00 – 5:00 PM
Tumor sonoreperfusion effect stimulated by using diagnostic ultrasound and microbubble
The hypovascular tumor tends to resist chemotherapy and radiation therapy. In this study, we used modified diagnostic ultrasound (DUS) to stimulate VX2 tumor of rabbit and Walker 256 tumor of rat with microbubble, trying to enhance the tumor blood flow. The DUS was operated at 4 MHz frequency, 10.5 cycles burst and 1-2 kHz PRF for treatment. The contrast ultrasound (CEUS) indicated that DUS treatment of only 10 min could significantly enhance the tumor flow or perfusion. The tumor perfusion enhancement effects could last at least 4h. In conclusion, diagnostic ultrasound can temporarily enhance the tumor blood perfusion with microbubble.
Speaker: Dr. Zheng Liu
A Novel Methodology for Automatic Measurement of Arterial Stiffness by Doppler Ultrasound
Doppler ultrasound now has been regarded as a reliable tool for measuring carotid-femoral pulse wave velocity (cfPWV), the “gold standard” of arterial stiffness. However, the cfPWV measurement can only be done by manual method, which is time-consuming, operator-dependent and may increase measurement errors. Therefore, an automated algorithm for cfPWV measurement is urgently needed. In this presentation, Dr. Wang will report a novel automatic methodology for cfPWV measuring and show its reproducibility and reliability. This work may provide a reliable, simple and reproducible approach for arterial stiffness evaluation in clinical settings.
Speaker: Zhen Wang

Tuesday, September 14: 4:00 – 5:00 PM
Evaluation the Relationship Between Ratio of Acceleration Time to Deceleration Time of Mitral Regurgitation Velocity and the Left Atrial Size in Dogs
LA/Ao ratio is the most common index for evaluating the size of LA. Left atrial (LA) size is a marker of cardiac prognosis in the general population and long‐standing mitral valvular insufficiency can cause volume overload of the LA. But suddenly elevated preload or pressure (due to rupture of the tendons) was unpredictable. In our study, we evaluate the relationship between ratio of acceleration time to deceleration time of mitral regurgitation velocity (MRAT/DT) and the left atrial size in dog who has MR. In the result, there was significant moderately correlated in the relationship between of MR AT/DT and LA/AO (pearson’s r=-0.6385, p<0.01). Due to the simply method and convenience, it has great potential to diagnosis the prelosd state of LA by estimating MR AT/DT ratio.
Speaker: Chih-hung Tsai
The voltage-dependent anion channel 1, a gatekeeper in myocardial injury
Voltage-dependent anion channel 1 (VDAC1), a channel that located in the outer membrane of mitochondria, controls the entry and exit of mitochondrial metabolites and ions. VDAC1 plays a crucial role in myocardial injury. We found that, during myocardial ischemia/reperfusion injury, VDAC1 was not only involved in mitochondria-mediated apoptosis, but also activated cardiomyocyte autophagy excessively, and resulted in autophagic cell death. Therefore, as the convergence point of survival and death signals in cardiomyocytes, VDAC1 is expected to become a new molecular target for the prevention and treatment of cardiovascular diseases.
Speaker: Zhangping Liao

Acoustic Life Science Co., Ltd.
Tuesday, September 14: 5:45 – 6:15 AM
Thursday, September 16: 5:45 – 6:15 AM ET

FUJIFILM VISUALSONICS, INC.
Monday, September 13: 1:15 – 2:15 PM ET
Vevo F2 and VADA: Bridging the gap between acoustics theory and preclinical imaging
In this webinar you will learn about the new Vevo F2 platform and how In this webinar you will learn about the new Vevo F2 platform and VADA (Vevo Advanced Data Acquisition), which gives you access to pre and post beamformed, Nyquist-sampled, RF data while providing feedback on modified transmit sequences within an easy-to-use graphical interface that assists instruction for students and new users.
Speakers: Lauren Wirtzfeld & Holly Lay

Ecare Electronics Science & Technology Co., Ltd.
Monday, September 13: 7:15 – 7:30 AM ET
Speaker: Renjie Song

Focused Ultrasound Foundation
Wednesday, September 15: 10:00 – 10:15 AM ET

Guangzhou Doppler Electronic Technologies Co., Ltd.
Monday, September 13: 2:15 – 2:30 PM ET
Novascan Phased Array Detector with TFM and its Application
This seminar introduces Novascan features and its applications in TFM, 3D imaging, XY two-dimensional scanning and stainless steel weld detection with double-sided array probe in detail.
Speaker: Alice Yi

scia Systems GmbH
Wednesday, September 15: 7:30 – 7:45 AM ET

Sonic Concepts
Wednesday, September 15: 2:30 – 2:45 PM ET

us4us
Monday, September 13: 7:30 – 7:45 AM ET
General overview of us4us products and services